Breaking News, Collaborations & Alliances

PolyPeptide Group Partners with Novavax on COVID-19 Vaccine

Will manufacture critical intermediates of Matrix-M adjuvant for vaccine candidate

By: Contract Pharma

Contract Pharma Staff

The PolyPeptide Group, a global contract development and manufacturing organization (CDMO) for peptide, peptidomimetic and other drug substances, has partnered with Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ novel coronavirus vaccine candidate, NVX-CoV2373.   PolyPeptide Group will produce two key intermediates used in the production of Matrix-M, the adjuva...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters